Related Experiment Video

Updated: Sep 12, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Mitophagy in the mechanisms of treatment resistance in solid tumors

Xiaoyi Yan1, Hui Ding1, Mengxiao Ren1

  • 1The Third Department of Geriatrics, Weifang People's Hospital, Weifang, Shandong, China.

Oncology Reviews
|August 5, 2025
PubMed

Insights

Mitophagy, a cellular process, promotes solid tumor survival and drug resistance. Understanding mitophagy mechanisms could reveal new strategies to overcome cancer treatment resistance.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Cancer treatment resistance is a major obstacle in solid tumor management.
  • Mitophagy, a selective form of autophagy, plays a role in tumor cell survival and proliferation.
  • Emerging evidence links mitophagy to drug resistance in various cancers.

Purpose of the Study:

  • To explore the mechanisms of mitophagy in solid tumor treatment resistance.
  • To analyze the impact of mitophagy on the biological characteristics of solid tumors.
  • To identify potential therapeutic targets for enhancing cancer treatment efficacy.

Main Methods:

  • Literature review of current research on mitophagy and cancer.
  • Analysis of studies investigating mitophagy's role in tumor cell survival and drug resistance.
  • Synthesis of findings to understand mitophagy's contribution to treatment resistance.

Main Results:

  • Mitophagy enhances tumor cell survival by clearing damaged mitochondria.
  • It contributes to resistance against various cancer therapies, including chemotherapy and targeted therapy.
  • Mitophagy modulates the tumor microenvironment and immune responses.

Conclusions:

  • Mitophagy is a key mechanism driving treatment resistance in solid tumors.
  • Targeting mitophagy presents a promising strategy to overcome drug resistance.
  • Further research into mitophagy pathways could lead to novel therapeutic interventions.
Keywords:
cellular autophagymitophagysolid tumorstreatment resistancetumor biology

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.0K